Introduction

Costco's recent decision to discontinue Focus Factor after a 16-year partnership triggered a Chapter 11 filing for Synergy CHC, the brand behind the functional beverage. The move clears the path for Reckitt Benckiser's Neuriva to capture shelf space in the brain health category.

What Happened

Synergy CHC filed for bankruptcy on September 4, 2026, in the U.S. Bankruptcy Court for the District of Columbia, following Costco's notification in July that it would stop carrying Focus Factor. The loss represented roughly 58% of Synergy's 2025 net revenue and triggered an $18.9 million debt acceleration, making reorganization inevitable.

Why This Matters

The collapse illustrates how quickly retail concentration can become a single point of failure. Focus Factor had established distribution across Walmart, Walgreens, Amazon, and BJ's, along with a 1 Pharmacist Recommended claim from the 2025-2026 Pharmacy Times survey, yet that couldn't offset the Costco decision. The bankruptcy serves as a cautionary example of reliance on one major retailer.

Key Takeaways

Neuriva, Reckitt's brain supplement, is already stocked in Costco's lineup, with the original 50-capsule bottle priced at $43.99. Reckitt has expanded the range with Neuriva Plus, Neuriva Ultra, and Neuriva Memory 3D, aligning with Costco's push toward premium wellness. Unlike Focus Factor, Neuriva carries no FTC settlements or efficacy lawsuits, giving it a regulatory advantage. Reckitt's H1 2026 results showed 2.7% like-for-like net revenue growth accelerating to 4.2% in Q2, a 60.9% gross profit margin, £419 million in free cash flow, and a 5% interim dividend increase alongside a £500 million share buyback.

Conclusion

With its existing Costco shelf presence, clean regulatory record, and expanding product portfolio, Reckitt is positioned to absorb displaced Focus Factor demand without adding structural risk. Investors tracking RBGLY should monitor how quickly Costco scales Neuriva and whether the shift translates into stronger financial results for the stock.